Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy
暂无分享,去创建一个
J. Benach | H. Broughton | C. Rauch | M. Debets | L. Pelletier | S. Gharbi | M. Hilgers | S. G. Sanfeliciano | L. Cano | M. Lallena | A. Zhang | R. Torres | Carmen Baquero | M. P. Ganado | Oscar Puig | Alfonso Espada | Jesus Gutiérrez | Elisabet Zapatero | Anna-Maria Russell | Sandra Gomez | Carmen Maria Perez | A. de Dios | N. Pulliam
[1] M. Goetz,et al. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups , 2021, NPJ breast cancer.
[2] T. Meyer,et al. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2 , 2021, Nature Communications.
[3] C. Falkson,et al. Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all? , 2021, Cancer.
[4] Jason D. Buenrostro,et al. Unlocking PDAC initiation with AP-1 , 2021, Nature Cancer.
[5] W. Sellers,et al. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders , 2020, Nature Cancer.
[6] P. Neven,et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Malumbres,et al. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. , 2020, Cancer cell.
[8] K. Shokat,et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition , 2019, Science.
[9] M. J. Chalmers,et al. A Decoupled Automation Platform for Hydrogen/Deuterium Exchange Mass Spectrometry Experiments , 2019, Journal of The American Society for Mass Spectrometry.
[10] T. Meyer,et al. Transient Hysteresis in CDK4/6 Activity Underlies Passage of the Restriction Point in G1. , 2019, Molecular cell.
[11] Christopher J. Williams,et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix , 2019, Acta crystallographica. Section D, Structural biology.
[12] Jane A. Endicott,et al. Structural insights into the functional diversity of the CDK–cyclin family , 2018, Open Biology.
[13] Christopher J. Williams,et al. MolProbity: More and better reference data for improved all‐atom structure validation , 2018, Protein science : a publication of the Protein Society.
[14] M. Goetz,et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Neven,et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Jian Du,et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer , 2017, Oncotarget.
[17] K. Gelmon,et al. Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.
[18] Ping Chen,et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.
[19] D. Agard,et al. Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase , 2016, Science.
[20] S. Loi,et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.
[21] S. Paternot,et al. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes , 2014, Cell cycle.
[22] Philip R. Evans,et al. How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.
[23] L. Hengst,et al. CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point , 2013, PLoS genetics.
[24] Karl A. Merrick,et al. A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. , 2013, Molecular cell.
[25] M. J. Chalmers,et al. HDX Workbench: Software for the Analysis of H/D Exchange MS Data , 2012, Journal of The American Society for Mass Spectrometry.
[26] P. Zwart,et al. Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.
[27] Clemens Vonrhein,et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER , 2012, Acta crystallographica. Section D, Biological crystallography.
[28] A. Sharff,et al. Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.
[29] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[30] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[31] A. Giordano,et al. Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.
[32] Rajiv Chopra,et al. Crystal structure of human CDK4 in complex with a D-type cyclin , 2009, Proceedings of the National Academy of Sciences.
[33] M. E. M. Noble,et al. The structure of CDK4/cyclin D3 has implications for models of CDK activation , 2009, Proceedings of the National Academy of Sciences.
[34] S. Blain,et al. Differential Modification of p27Kip1 Controls Its Cyclin D-cdk4 Inhibitory Activity , 2007, Molecular and Cellular Biology.
[35] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[36] Anindya Dutta,et al. Autocatalytic Phosphorylation of CDK2 at the Activating Thr160 , 2007, Cell cycle.
[37] U. Schulze-Gahmen,et al. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. , 2006, Journal of medicinal chemistry.
[38] J. Massagué,et al. G1 cell-cycle control and cancer , 2004, Nature.
[39] G. Peters,et al. Induced Expression of p16INK4a Inhibits Both CDK4- and CDK2-Associated Kinase Activity by Reassortment of Cyclin-CDK-Inhibitor Complexes , 1999, Molecular and Cellular Biology.
[40] J. Massagué,et al. Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4* , 1997, The Journal of Biological Chemistry.
[41] J. LaBaer,et al. New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.
[42] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[43] R. Weinberg,et al. Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.
[44] J. Saiz,et al. Right‐sided non‐recurrent laryngeal nerve without any vascular anomaly: an anatomical trap , 2021, ANZ journal of surgery.
[45] Birgit Kasch,et al. Next Generation , 2016, Im OP.